Immucell Corp (ICCC) Stock Price, Quote & News

Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus...

Industry: Biotechnology

Sector: Healthcare

Phone: 207 878 2770

Website: immucell.com

Address:

56 Evergreen Drive, Portland, United States

StocktwitsNews Dec. 26 at 5:38 PM

The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell $NVDA $SIDU $CPNG $VNDA $ICCC https://stocktwits.com/news/equity/markets/christmas-party-stocks-still-ongoing-2025/cLeULetRED2

0 · Reply

Few_erish Dec. 26 at 4:34 PM

$ICCC Small tape, big move, 6.11 up 5.34 but only 193,173 volume, that’s thin liquidity so every print matters

0 · Reply

UnicornPicks Dec. 26 at 2:42 PM

$ICCC $OPTX $PPSI $SIDU ideas for scalp!

0 · Reply

DARKP00L Dec. 26 at 2:37 PM

$ICCC 09:31 on Dec. 26 2025 ImmuCell Puts Re-Tain On Pause After FDA Letter #tradeideas

0 · Reply

Stock_Catcher Dec. 26 at 2:33 PM

$ICCC thin one

0 · Reply

OpenOutcrier Dec. 26 at 1:11 PM

$ICCC (-11.7% pre) ImmuCell pauses Re-Tain development after FDA rejection, shifts to First Defense https://ooc.bz/l/88396

0 · Reply

InterpolationIsle Dec. 25 at 4:57 PM

$ICCC Market behavior suggests the name is transitioning from speculation toward proof‑based evaluation. The business must show that scaling does not introduce uncontrolled risk. Failure to deliver would likely trigger renewed valuation compression. Over time, credibility will hinge on repeatable performance.

1 · Reply

JohnTrack Dec. 24 at 6:32 PM

$ICCC FDA Incomplete Letter for Re-Tain, bad news... https://www.rapidticker.com/news/iccc-immucell-announces-strategic-focus-on-212aba

0 · Reply

Bogwood Dec. 24 at 6:20 PM

$ICCC 🤢🤮

0 · Reply

TommyTwenty Dec. 16 at 12:45 AM

$ICCC https://rollcall.com/2025/12/15/house-clears-whole-milk-for-school-menus/

0 · Reply

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

Nov 14, 2025, 11:01 AM EST - 6 weeks ago

ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 6 weeks ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

Nov 6, 2025, 4:05 PM EST - 7 weeks ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

Nov 4, 2025, 4:05 PM EST - 7 weeks ago

ImmuCell Announces Onboarding of New CEO and Related Management Changes

Oct 7, 2025, 4:05 PM EDT - 2 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

Sep 29, 2025, 4:05 PM EDT - 3 months ago

ImmuCell Announces Selection of its Next President and CEO

Aug 15, 2025, 11:04 AM EDT - 4 months ago

ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:05 PM EDT - 4 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

Aug 12, 2025, 4:05 PM EDT - 4 months ago

ImmuCell Announces Bank Debt Refinancing

Aug 7, 2025, 8:00 AM EDT - 5 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025

Jul 9, 2025, 8:00 AM EDT - 6 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

Jun 25, 2025, 8:00 AM EDT - 6 months ago

ImmuCell Embarks on CEO Succession Planning Process

Jun 5, 2025, 6:30 AM EDT - 7 months ago

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

May 15, 2025, 10:19 AM EDT - 8 months ago

ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 8 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

May 12, 2025, 8:42 AM EDT - 8 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

Apr 8, 2025, 4:05 PM EDT - 9 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

Apr 2, 2025, 4:05 PM EDT - 9 months ago

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Feb 26, 2025, 11:44 AM EST - 10 months ago

ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 10 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Feb 20, 2025, 8:19 AM EST - 11 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Jan 16, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

Jan 9, 2025, 4:05 PM EST - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

Nov 14, 2024, 11:09 AM EST - 1 year ago

ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

Oct 8, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

Aug 14, 2024, 12:18 PM EDT - 1 year ago

ImmuCell Corporation (ICCC) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024

Jul 9, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

Jun 5, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

May 15, 2024, 1:48 PM EDT - 1 year ago

ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024

May 8, 2024, 1:00 PM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

Apr 9, 2024, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

Feb 28, 2024, 11:58 AM EST - 1 year ago

ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Feb 16, 2024, 9:30 AM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Jan 8, 2024, 4:05 PM EST - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

Nov 14, 2023, 2:36 PM EST - 2 years ago

ImmuCell Corporation (ICCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

Nov 7, 2023, 12:15 PM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Oct 5, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

Aug 29, 2023, 8:00 AM EDT - 2 years ago

ImmuCell Announces Submission of CMC Technical Section to the FDA

Aug 11, 2023, 4:48 PM EDT - 2 years ago

ImmuCell Corporation (ICCC) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

Aug 7, 2023, 12:00 PM EDT - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

Jul 11, 2023, 4:05 PM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

StocktwitsNews Dec. 26 at 5:38 PM

0 · Reply

Few_erish Dec. 26 at 4:34 PM

$ICCC Small tape, big move, 6.11 up 5.34 but only 193,173 volume, that’s thin liquidity so every print matters

0 · Reply

UnicornPicks Dec. 26 at 2:42 PM

$ICCC $OPTX $PPSI $SIDU ideas for scalp!

0 · Reply

DARKP00L Dec. 26 at 2:37 PM

$ICCC 09:31 on Dec. 26 2025 ImmuCell Puts Re-Tain On Pause After FDA Letter #tradeideas

0 · Reply

Stock_Catcher Dec. 26 at 2:33 PM

$ICCC thin one

0 · Reply

OpenOutcrier Dec. 26 at 1:11 PM

$ICCC (-11.7% pre) ImmuCell pauses Re-Tain development after FDA rejection, shifts to First Defense https://ooc.bz/l/88396

0 · Reply

InterpolationIsle Dec. 25 at 4:57 PM

1 · Reply

JohnTrack Dec. 24 at 6:32 PM

$ICCC FDA Incomplete Letter for Re-Tain, bad news... https://www.rapidticker.com/news/iccc-immucell-announces-strategic-focus-on-212aba

0 · Reply

Bogwood Dec. 24 at 6:20 PM

$ICCC 🤢🤮

0 · Reply

TommyTwenty Dec. 16 at 12:45 AM

$ICCC https://rollcall.com/2025/12/15/house-clears-whole-milk-for-school-menus/

0 · Reply

CEOBuysDisclosures Dec. 4 at 11:15 PM

$ICCC CEO purchased 6,030 shares at $5.23 for a total of $31,528. te Boekhorst Paul Francis Olivier now owns 9,738 shares. https://ceo-buys.com

0 · Reply

theRooster007 Dec. 4 at 8:36 PM

$ICCC

0 · Reply

ZacksResearch Dec. 4 at 4:16 PM

$ICCC’s cattle-health play is starting to look like a quiet breakout story. Their two antibiotic-free products are driving margin recovery and real-world adoption — and the stock is already reacting. See the full setup here 👉 https://www.zacks.com/stock/news/2799680/immucells-two-product-edge-in-cattle-health-fuels-growth?cid=sm-stocktwits-2-2799680-teaser-23445&ADID=SYND_STOCKTWITS_TWEET_2_2799680_TEASER_23445

0 · Reply

ZacksResearch Dec. 4 at 3:16 PM

$ICCC up 17.4% in the past year — outpacing the industry and $SPX! 🚀 ImmuCell’s innovative First Defense and Re-Tain products are driving real on-farm results, tackling costly cattle health issues without routine antibiotics. With improved margins and a $4.5-million swing from a net loss to net income in 2025, ICCC is leveraging strong operational and financial momentum. Discover how this non-Pharma pharma is reshaping cattle health here 👉 https://www.zacks.com/stock/news/2799680/immucells-two-product-edge-in-cattle-health-fuels-growth?cid=sm-stocktwits-2-2799680-body-23446&ADID=SYND_STOCKTWITS_TWEET_2_2799680_BODY_23446

0 · Reply

TommyTwenty Dec. 3 at 11:53 PM

$ICCC 2 big insider buys recently

1 · Reply

CEOBuysDisclosures Dec. 3 at 11:20 PM

$ICCC CEO purchased 9,785 shares at $4.97 for a total of $48,588. te Boekhorst Paul Francis Olivier now owns 9,785 shares. https://ceo-buys.com

0 · Reply

theRooster007 Nov. 29 at 1:21 AM

$ICCC

0 · Reply

theRooster007 Nov. 28 at 4:28 PM

$ICCC

0 · Reply

ZacksResearch Nov. 20 at 12:52 PM

$ICCC sinking even with the fundamentals moving in the right direction — that’s a tough tape. The teaser shows stronger margins and a rebound in EPS, but backlog dynamics hit quarterly sales, overshadowing management’s push on improving operations. Classic disconnect. Full breakdown here 👉 https://www.zacks.com/stock/news/2793410/iccc-stock-down-despite-yy-q3-earnings-improvement-margin-strength?cid=sm-stocktwits-2-2793410-teaser-21752&ADID=SYND_STOCKTWITS_TWEET_2_2793410_TEASER_21752

0 · Reply

ZacksResearch Nov. 20 at 11:52 AM

$ICCC shares drop 23% in a month despite profitability boost! 📉🤔 🔍 Gross margin surged to 43% from 26% in the third quarter 💰 Net loss narrowed significantly from $702K to $140K in the third quarter 📈 Adjusted EBITDA jumped to $751K from $196K a year earlier What’s driving the sell-off? Explore the details here 👉 https://www.zacks.com/stock/news/2793410/iccc-stock-down-despite-yy-q3-earnings-improvement-margin-strength?cid=sm-stocktwits-2-2793410-body-21751&ADID=SYND_STOCKTWITS_TWEET_2_2793410_BODY_21751

0 · Reply

theRooster007 Nov. 18 at 5:51 PM

$ICCC added again

0 · Reply

theRooster007 Nov. 17 at 8:01 PM

$ICCC Where IS 12

0 · Reply

Market Cap	52.47M
Revenue (ttm)	26.49M
Net Income (ttm)	-2.16M
EPS (ttm)	N/A
PE Ratio	22.38
Forward PE	N/A
Profit Margin	-8.15%
Debt to Equity Ratio	0.32

Volume	336,039
Avg Vol	18,792
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	0%
Beta	0.20
Analysts	Strong Buy
Price Target	$14.00